ArticleBMC anesthesiology2026
Physicochemical stability of sufentanil and esketamine containing analgesic mixtures applied for patient-controlled intravenous analgesia.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSufentanil combined with esketamine for patient-controlled intravenous analgesia (PCIA) is an efficient options for postoperative pain control, which can result in a shortened hospital stay. However, no commercially formulated admixture of these two agents is currently available for clinical use. Furthermore, to date, no published data exist regarding the physicochemical stability of sufentanil and esketamine co-dissolved in 0.9% sodium chloride injection. The study aims to assess the stability of sufentanil and esketamine in infusion at both room temperature (25 °C) and refrigerated conditions (4 °C).
methodsCommercial available injectable formulations of sufentanil and esketamine were were aseptically combined and diluted with 0.9% sodium chloride injection to yield final concentrations of 1.0 µg/mL sufentanil and 0.25, 0.5, or 1.0 mg/mL esketamine. The resulting admixtures were stored in polyvinyl chloride (PVC) infusion bags and assessed for compatibility and stability over 14 days at 4 °C and over 48 h at 25 °C. Stability was evaluated through visual inspection (for precipitation or discoloration), pH measurement, and quantitative analysis of drug concentrations using validated liquid chromatography-tandem mass spectrometry (LC-MS/MS).
resultsAll admixtures remained physically stable-no precipitation, turbidity, or color change was observed throughout the study period. The pH values varied by less than 0.80 units across all batches and time points under both storage conditions. Both sufentanil and esketamine retained ≥ 95% of their initial concentrations at all tested time points and temperatures.
conclusionSufentanil (1.0 µg/mL) combined with esketamine (0.25, 0.5, or 1.0 mg/mL) in 0.9% sodium chloride injection demonstrated chemical and physical stability for up to 14 days under refrigerated storage and for up to 48 h under room-temperature conditions when contained in PVC infusion bags.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.